Page last updated: 2024-09-03

c 1311 and Angiogenesis, Pathologic

c 1311 has been researched along with Angiogenesis, Pathologic in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Brillowska-Dąbrowska, A; Konopa, J; Paradziej-Łukowicz, J; Peszyńska-Sularz, G; Skwarska, A	1

Other Studies

1 other study(ies) available for c 1311 and Angiogenesis, Pathologic

Article	Year
Anticancer imidazoacridinone C-1311 inhibits hypoxia-inducible factor-1α (HIF-1α), vascular endothelial growth factor (VEGF) and angiogenesis. Cancer biology & therapy, 2011, Oct-01, Volume: 12, Issue:7 Topics: Aminoacridines; Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Binding Sites; Cell Line, Tumor; Cell-Free System; Colonic Neoplasms; Dose-Response Relationship, Drug; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Melanoma; Mice; Mice, Inbred C57BL; Neovascularization, Pathologic; Response Elements; Tumor Suppressor Protein p53; Vascular Endothelial Growth Factor A	2011

Article

Year

Anticancer imidazoacridinone C-1311 inhibits hypoxia-inducible factor-1α (HIF-1α), vascular endothelial growth factor (VEGF) and angiogenesis.

Cancer biology & therapy, 2011, Oct-01, Volume: 12, Issue:7

Topics: Aminoacridines; Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Binding Sites; Cell Line, Tumor; Cell-Free System; Colonic Neoplasms; Dose-Response Relationship, Drug; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Melanoma; Mice; Mice, Inbred C57BL; Neovascularization, Pathologic; Response Elements; Tumor Suppressor Protein p53; Vascular Endothelial Growth Factor A

2011